YTS109 for children with hard-to-treat autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Eyes & vision, Heart & circulation, Immune system & allergy, Mouth & dental, Skin clinical trials.
This trial tests a new treatment (YTS109) for children with certain autoimmune diseases that have not responded to standard therapies. The treatment targets B cells, which are part of the immune system, to help calm down the immune attack.
Summary written for real people, not researchers, by Clin2.
Who can take part
- The child must be between 5 and under 18 years old.
- They must have a type of autoimmune disease (like lupus, scleroderma, myositis, Sjögren's, vasculitis, or antiphospholipid syndrome) that is active or severe.
- Their disease must not have improved with standard treatments, or it came back after getting better.
- They must have CD19-positive B cells in their blood (a type of immune cell).
- They must be reasonably healthy in terms of heart, kidney, liver, and blood counts.
- Females who could become pregnant must not be pregnant and must avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This early-phase trial tests a new drug called TI-0032-III for people with several autoimmune diseases that haven't gotten better with standard treatments. It aims to see if the drug can safely reduce disease activity and offer a new option for people who have few choices left.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Hear when a new Idiopathic Inflammatory Myopathies (IIMs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.